LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Strona główna・Stock List・Puma Biotechnology Inc

Puma Biotechnology Inc

Closed

SectorHealthcare

5.52 2.41

Buy Sell

Overview

Share price change

24h

Current

Min

5.33

Max

5.64

Key metrics
By Trading Economics
Income	3M 8.8M
Sales	2M 54M
P/E Sector Avg	7.297 77.671
EPS	0.21
Profit margin	16.235
Employees	172
EBITDA	2.7M 13M

Recommendations
By TipRanks
Recommendations	Sell
12 Months Forecast	-35.19% downside

Market Stats
By TradingEconomics
Market Cap	18M 272M
Previous open	3.11
Previous close	5.52

News Sentiment

By Acuity

28%

72%

77 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

3.07 / 3.075 Support & Resistance

Puma Biotechnology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

9 gru 2025, 22:13 UTC

Earnings

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9 gru 2025, 21:40 UTC

Earnings

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9 gru 2025, 18:51 UTC

Acquisitions, Mergers, Takeovers

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9 gru 2025, 16:57 UTC

Major Market Movers

Clear Secure Rises on Medicare Identity Verification Contract

9 gru 2025, 23:46 UTC

Market Talk

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9 gru 2025, 23:46 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings Stake in Lenovo Now at 32.34%

9 gru 2025, 23:45 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9 gru 2025, 23:44 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9 gru 2025, 23:43 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9 gru 2025, 23:43 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9 gru 2025, 23:35 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9 gru 2025, 22:42 UTC

Earnings

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9 gru 2025, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 gru 2025, 21:48 UTC

Market Talk

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9 gru 2025, 21:36 UTC

Earnings

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9 gru 2025, 21:36 UTC

Earnings

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9 gru 2025, 21:36 UTC

Earnings

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9 gru 2025, 21:36 UTC

Earnings

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9 gru 2025, 21:36 UTC

Earnings

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9 gru 2025, 20:28 UTC

Market Talk

Oil Futures Decline for Second Straight Session -- Market Talk

9 gru 2025, 20:27 UTC

Acquisitions, Mergers, Takeovers

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9 gru 2025, 20:27 UTC

Acquisitions, Mergers, Takeovers

Teck Reports Voting Results From Special Meeting of Hldrs

9 gru 2025, 20:26 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9 gru 2025, 20:21 UTC

Market Talk

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9 gru 2025, 19:52 UTC

Earnings

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9 gru 2025, 19:17 UTC

Earnings

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9 gru 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 gru 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 gru 2025, 17:11 UTC

Earnings

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Peer Comparison

Price change

Puma Biotechnology Inc Forecast

Price Target

By TipRanks

-35.19% downside

12 Months Forecast

Average 3.5 USD -35.19%

High 5 USD

Low 2 USD

Based on 2 Wall Street analysts offering 12 month price targets forPuma Biotechnology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Sell

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Puma Biotechnology Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.07 / 3.075Support & Resistance

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

77 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.